Overview

Adjuvant Systemic Treatment for (ER)-Positive HER2-negative Breast Carcinoma in Women Over 70 According to Genomic Grade (GG): Chemotherapy + Endocrine Treatment Versus Endocrine Treatment

Status:
Active, not recruiting

Trial end date:
2026-03-01

Target enrollment:

Participant gender:

Summary

The purpose of the study is to evaluate the benefit of adjuvant chemotherapy on overall survival for elderly patients with breast cancer, in a sub group with a high risk of relapse according to Genomic Grade test.

Phase:

Phase 3

Details

Lead Sponsor:

UNICANCER

Treatments:

Aromatase Inhibitors
Cyclophosphamide
Doxorubicin
Tamoxifen